湖北龙辰科技第二次闯关北交所。 早在2022年12月，龙辰科技的IPO申请就获得了北交所受理。 来源：北交所官网 2023年，龙辰科技两次上会先后遭遇"暂缓审议"、"未通过"，同年终止审核。 彼时的核心痛点在于，公司与江苏双凯电子有限公司（简称"江苏双凯"）之间关联交易的合理性。 为扫清障碍，龙辰科技在2024年以4500万元收购江苏双凯剩余股权，并于年底重启上市计划。 2025年6月，公司IPO申请再获北交所受理，目前处于"已问询"阶段。不过，公司仍面临净利润波动大、 毛利率持续下滑、行业产能过剩等风险。 二度闯关北交所，龙辰科技这次能顺利上岸吗？ 项目介绍： 公司简称：龙辰科技 公司全称：湖北龙辰科技股份有限公司 IPO进展：一询未回复 成立时间：2003年11月6日 控股股东：林美云为控股股东、实际控制人，合计控制54.08%股权。 主营业务：薄膜电容器相关BOPP薄膜材料的研发、生产和销售，产品主要分为基膜、金属化膜两大 类。 行业地位：公司为高新技术企业，2021年被认定为国家级专精特新"小巨人"企业、湖北省专精特新"小 巨人"企业、湖北省支柱产业细分领域隐形冠军培育企业。根据中国合成树脂协会高功能 ...

Group 1: New IPOs and Market Overview - This week (October 13 to 17), there are 5 new stocks available for subscription, including 1 from the Shanghai Main Board, 1 from the Shenzhen Main Board, and 3 from the Sci-Tech Innovation Board [1][2] - Xi'an Yicai ranks second in total shares issued among new stocks in the Shanghai and Shenzhen markets since 2025, indicating a potentially high probability of winning the subscription [1] - Marco Polo, a new stock on the Shenzhen Main Board, has an issue price of 13.75 yuan and a price-to-earnings ratio of 14.27, compared to the industry average of 28.02 [2] Group 2: Company Profiles and Financials - He Yuan Bio, launching on October 14, focuses on plant-based recombinant protein technology and has 8 products in development or on the market. Its core product, HY1001, is the first recombinant human albumin drug approved in China, addressing a market size of approximately 30% of human serum albumin [1][3] - Marco Polo is the largest manufacturer and seller of building ceramics in China, with a total fundraising amount of 1.643 billion yuan from its IPO [2] - Xi'an Yicai, a leading supplier of 12-inch silicon wafers, aims to raise 4.9 billion yuan through its IPO [4] - Biotech company Bibet focuses on innovative drug development for major diseases and plans to raise 2.005 billion yuan in its IPO [4] Group 3: Upcoming IPO Meetings - Three companies are scheduled for IPO meetings this week: Youxun Co. and Angrui Micro on the Sci-Tech Innovation Board, and Tian Su Measurement on the Growth Enterprise Market [5][6] - Youxun Co. specializes in optical communication chips and aims to raise 809 million yuan [6] - Angrui Micro focuses on RF and analog integrated circuit design, with a planned fundraising of 2.067 billion yuan [6] - Tian Su Measurement provides third-party measurement and testing services, targeting a fundraising of 424 million yuan [6]

Company Overview - Klarna is a Swedish-based technology firm specializing in online financial services and payment processing for e-commerce, particularly known for its 'buy now, pay later' services [4] - The company has approximately 111 million customers and 790,000 businesses using its services across 26 countries, handling $112 billion in gross merchandise volume [3] IPO Details - Klarna's IPO raised a total of $1.37 billion, with shares opening at $52 and a market cap of around $15 billion one month post-offering [1][2] - The initial share price was set at $40, which was $4 higher than the midpoint of the estimated range, with a total offering of 34,311,274 shares [2] Market Position and Performance - Goldman Sachs views Klarna as a market leader in Buy-Now-Pay-Later (BNPL) solutions, particularly strong in Europe, and expects it to gain market share over time [8] - The stock currently has a Strong Buy rating from analysts, with a price target of $55 indicating a potential 12-month gain of approximately 42% [9] Recent Market Activity - The third quarter of 2025 saw a significant increase in IPO activity, with 60 IPOs raising a total of $14.6 billion, marking a substantial rise from the previous year [6] - Klarna's performance is part of a broader trend in the online financial services sector, which is attracting investor interest [7]

Core Viewpoint - The company, Huolala, has consistently submitted IPO applications every six months since March 2023, raising questions about its genuine intent to go public versus maintaining the appearance of being on the verge of an IPO [4][5][20]. Group 1: IPO Submission Patterns - Huolala has submitted five IPO applications, each followed by expiration, suggesting a strategic approach to maintain market presence and investor confidence [4][5]. - The regularity of submissions, approximately every 180 days, indicates a potential sixth submission around October 2025, unless the company decides to halt this pattern, which could signal a shift in strategy [9][21]. Group 2: Implications of Non-Listing - Submitting IPO applications without actual listing allows the company to project a compliant and transparent image, maintaining the illusion of readiness for public markets [5][12]. - The company benefits from ongoing public disclosures, enhancing its visibility and perceived stability without the pressures of being publicly traded [12][17]. - This strategy allows Huolala to retain control over its narrative and valuation, avoiding the volatility associated with public market fluctuations [13][25]. Group 3: Market Conditions and Strategic Timing - Current market conditions, particularly low valuations in the Hong Kong stock market, discourage immediate listing, as it could lead to unfavorable pricing for early investors [10][11]. - The company may be waiting for more favorable market conditions or regulatory changes before proceeding with an IPO [22]. Group 4: Narrative Management - The act of submitting IPO applications serves as a form of narrative management, allowing the company to maintain a competitive presence in the market without the need for immediate listing [19][20]. - Each submission is accompanied by updates and media engagement, reinforcing the company's ongoing relevance and operational stability [20]. Group 5: Future Considerations - If the anticipated sixth submission does not occur, it could indicate a significant strategic shift, such as exploring alternative funding routes or a strong enough business performance to forgo the need for public market validation [24][25].

本次冲击上市，中国铀业拟募集资金约41.1亿元。 （文章来源：北京商报） 招股书显示，中国铀业是专注于天然铀和放射性共伴生矿产资源综合利用业务的矿业公司，报告期内主 要从事天然铀资源的采冶、销售及贸易，以及独居石、铀钼等放射性共伴生矿产资源综合利用及产品销 售。据悉，公司主板IPO于2024年6月20日获得受理，当年7月18日进入问询阶段，2025年9月5日上会获 得通过，并于同年9月8日提交注册。 北京商报讯近日，深交所官网显示，中国铀业股份有限公司（以下简称"中国铀业"）主板IPO注册生 效。 ...

Core Viewpoint - Beijing Angrui Microelectronics Technology Co., Ltd. is set to undergo its IPO review on October 15, 2023, as it aims to raise approximately 2.067 billion yuan for various projects [1] Company Overview - Angrui Micro is focused on integrated circuit design in the RF and analog fields, primarily engaged in the research, design, and sales of RF front-end chips, RF SoC chips, and other analog chips [1] - The company’s IPO was accepted on March 28, 2025, and it entered the inquiry phase on April 15 of the same year [1] Fundraising and Investment Plans - The company plans to raise around 2.067 billion yuan, which will be allocated to the following projects: - R&D and industrialization upgrades for 5G RF front-end chips and modules - R&D and industrialization upgrades for RF SoC - Construction of headquarters and R&D center [1]

智谱方面表示，公司目前近50个岗位需求待招，希望大家帮助广为传播，广纳贤人。据智谱官方发布招 聘信息显示，目前公司在招岗位包括多模态生成算法工程师、推理优化工程师、及产品和业务等岗位。 （文猛） 责任编辑：石秀珍 SF183 新浪科技讯 10月12日上午消息，针对近期网络流传"AI六小龙"企业智谱IPO（首次公开募股）前夕裁员 传闻，智谱方面回应新浪科技称："感谢现阶段对智谱的高度关注，网上不实造谣行为属个例"。 ...

Core Insights - The IPO market is experiencing significant activity, particularly in the Hong Kong stock market, with a notable number of companies filing for listings, including many dual-listed A+H companies [2][17] - New listings have shown remarkable performance, with companies like Aomisen and Jinye International Group achieving substantial first-day gains and record oversubscription rates [6][8][9][10] Recent Approvals - Guanghetong has received approval for its listing on the Hong Kong Stock Exchange, with projected revenues increasing from 5.203 billion yuan in 2022 to 6.971 billion yuan in 2024 [3] - Tongrentang Medical has also passed its hearing, reporting revenues of 910 million yuan in 2022, with a projected increase to 1.175 billion yuan in 2024 [4] - Haixi New Drug has been approved for listing, with revenues expected to grow from 212.5 million yuan in 2022 to 466.7 million yuan in 2024 [5] New Listings - Aomisen debuted on the Beijing Stock Exchange with a first-day surge of 349.8%, achieving a market capitalization of 2.97 billion yuan [6] - Jinye International Group listed on the Hong Kong Stock Exchange with a staggering oversubscription rate of 11,464.7 times, closing up 330% on its first day [8] - Zhida Technology's IPO was marked by a 192.14% increase on its first trading day, establishing it as a leader in the home electric vehicle charging solutions market [9] - Changfeng Pharmaceutical's shares opened at 48 HKD, a 225.42% increase, with a revenue CAGR of 31.9% projected from 2022 to 2024 [10] Recent Filings - Lantu Motors has filed for a listing on the Hong Kong Stock Exchange, showing significant revenue growth from 6.052 billion yuan in 2022 to 19.361 billion yuan in 2024 [11] - Chengyi Biotechnology has initiated its IPO process, focusing on developing new oral small molecule drugs for cardiovascular and inflammatory diseases [12] - Senyi Medical has filed for an IPO, recognized as a leading AI medical solution provider in China [13] - Annuo Youda has submitted its prospectus for an IPO, specializing in molecular diagnostics and IVD medical devices [14] - WeDoctor is making another attempt to list on the Hong Kong Stock Exchange after previous unsuccessful attempts [15] Market Trends - In the first three quarters of 2025, Chinese companies have shown increased IPO activity, with 161 listings, a 25.8% year-on-year increase, and a total fundraising amount of approximately 193.73 billion yuan [17] - The Hong Kong market saw 60 Chinese companies listed in the first three quarters, reflecting a 53.8% increase compared to the previous year [18]

Group 1 - The core point of the news is that Shanxi Tengmao Technology Co., Ltd. has initiated the IPO guidance for the Beijing Stock Exchange, with West Securities as the guiding institution and Beijing Kangda Law Firm as the legal advisor [1] - Tengmao Technology specializes in the research, production, and sales of catalytic cracking catalysts, additives, and molecular sieves, positioning itself within the refining catalyst industry [2] - In the first half of 2025, Tengmao Technology achieved revenue of 141 million yuan, representing a year-on-year growth of 40.22%, and a net profit attributable to shareholders of 33.698 million yuan, reflecting a year-on-year increase of 48.76% [2] Group 2 - This marks the second attempt by Tengmao Technology to pursue an IPO on the Beijing Stock Exchange, having previously submitted an application in October 2023, which was later withdrawn in March 2024 [2] - The company had a significant supplier relationship with Chenhao Chemical, which was its largest supplier in 2020 and 2021, with procurement amounts of 42.8641 million yuan and 38.7276 million yuan, respectively, accounting for 28.93% and 26.92% of operating costs [4] - The cooperation model with Chenhao Chemical changed in 2022 from purchasing finished products to a processing commission model, with Chenhao Chemical's products primarily sold to Tengmao Technology [4][6]

（来源：IPO热点） 你常去的景点即将跑出一个IPO。 不久前，江苏瘦西湖文化旅游股份有限公司（简称"瘦西湖"）向港交所递交招股书，光大证券国际为独 家保荐人。 始于扬州市，瘦西湖身后站着一位女董事长——现年55岁的徐顺美。早年她从景点导游干起，一路做到 公司管理层，打造瘦西湖船娘的核心品牌，带领公司成长为江苏省内第二大水上游览服务商。 目之所及，今年黄金周爆了。正如大家朋友圈，定位天南地北，境内境外游火爆，数据显示假期前半程 全社会跨区域人员流动量更是达到12.43亿人次，再次创造历史。 从女导游到董事长 去IPO了 "故人西辞黄鹤楼，烟花三月下扬州。"李白一首送别诗捧红了扬州，也带火了这里的核心景区——瘦西 湖。 来源：市场资讯 资料显示，出生于1970年，徐顺美早年毕业于南京师范大学，从景点导游员干起，一路做到瘦西湖公园 秘书处处长、管理处副主任、办公室主任。直到2011年担任公司总经理一职，后来升任董事长。 自2007年以来，徐顺美全程参与景区的创建管理，着手打造生态画舫、瘦西湖船娘等品牌，完成"瘦西 湖-古运河-大运河"的线路升级，推出餐饮、商品零售、会务接待、绿化养护等配套项目，以及"夜游扬 州" ...